NIFTY, SENSEX dip; Infosys, L&T, Lupin, Nestle India, Zydus Lifesciences among buzzing stocks

Benchmark indices NIFTY and SENSEX declined on Thursday, July 24, amid a fall in IT and banking stocks and continuous foreign fund outflows.

SENSEX slipped 528 points to 82,198, while NIFTY dipped 0.58% to 25,073 at 12:45 pm.

From the NIFTY50 firms, Nestle India, Trent, Tech Mahindra, Shriram Finance, Reliance, Coal India, Infosys and HCL Tech were among the biggest laggards.

However, Eternal, Dr Reddy's, Tata Motors, Tata Consumer Products, Jio Financial Services and Tata Steel were among the gainers.

Buzzing stocks on July 24; check list

The company's consolidated net profit stood at ₹6,921 crore in Q1 FY26, up 8.68% from ₹6,368 crore in the year-ago period. Sequentially, post-tax profit slid 1.59% from ₹7,033 crore.

Its revenue from operations advanced 7.5% to ₹42,279 crore in the reporting quarter as against ₹39,315 crore in the year-ago quarter. On a sequential basis, it rose 3.3%. The results were better than street estimates.

The IT services firm projected an annual revenue growth forecast in range of 1% to 3%.

It has bagged an order from the Andhra Pradesh Capital Region Development Authority to develop an integrated Andhra Pradesh State Secretariat & HoD offices and 21 residential towers. It also secured an order to construct residential towers in Mumbai.

Additionally, L&T Oman's B&F division received a repeat order for the construction of a premium office space in Muscat.

The stock is down 0.56% to ₹3,465.4 apiece on the NSE.

Liraglutide injection is used to improve glycemic control in adults and pediatric patients aged 10 years or above with type 2 diabetes mellitus.

Glucagon injection is "indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients," it said.

Market coupling is a model used in energy markets to set a single, uniform price for electricity across different trading platforms or exchanges.

Ibrutinib is used in the treatment of chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) with 17p deletion and Waldenstrom's macroglobulinemia (WM).